Alpha-synuclein levels in cerebrospinal fluid (CSF) may predict the development of psychotic symptoms in patients with prodromal Alzheimer’s disease (AD), a new study finds.
The development of psychotic symptoms is associated with poor prognosis in patients with AD. Researchers in Spain tested whether CSF biomarkers collected during the prodromal phase of AD could predict the subsequent development of psychotic symptoms.